Is Europe a good place to run CNS trials?
In Europe, nearly one million people suffer from Multiple Sclerosis (MS). MS patients are referred to specialized facilities (MS centers). As a result, in one country in CEE, 15 MS centers treat over 20,000 patients, providing access to more than 1,000 at one site.
In 2019, the incidence of Alzheimer's disease and other dementias in Europe was approximately 188 per 100,000. The total number of people living with dementia in EU countries is expected to increase by approximately 60% over the next two decades, reaching 14.3 million by 2040. In the majority of European countries, specialized societies care for Alzheimer's patients, who are then easily identifiable for clinical trials.
Below is a brief summary of our experience and key figures in neurology and psychiatry in Europe. Pharmnet has considerable clinical trial experience in neurology and psychiatry with medical experts within the team, including two psychiatrists. The Pharmnet team would be happy to provide you with more detailed information on our experience that is particular to your development program.